Furthermore, mutations in SMARCB1 and SMARCA4 lead to widespread changes in the H3K27Me3 distribution, changing gene expression patterns, and suggesting that PRC2 can be targeted in these cancers [58, 81, 82]. This evidence concerns the gene SMARCB1 and cancer.